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Available online 24 December 2015In addition to their stem/progenitor properties, mesenchymal stem cells (MSCs) also exhibit potent effector (an-
giogenic, antiinﬂammatory, immuno-modulatory) functions that are largely paracrine in nature. It is widely be-
lieved that effector functions underlie most of the therapeutic potential of MSCs and are independent of their
stem/progenitor properties. Here we demonstrate that stem/progenitor and effector functions are coordinately
regulated at the cellular level by the transcription factor Twist1 and speciﬁed within populations according to
a hierarchical model. We further show that manipulation of Twist1 levels by genetic approaches or by exposure
to widely used culture supplements including ﬁbroblast growth factor 2 (Ffg2) and interferon gamma (IFN-
gamma) alters MSC efﬁcacy in cell-based and in vivo assays in a predictable manner. Thus, by mechanistically
linking stem/progenitor and effector functions our studies provide a unifying framework in the form of an MSC
hierarchy that models the functional complexity of populations. Using this framework, we developed a CLinical
Indications Prediction (CLIP) scale that predicts how donor-to-donor heterogeneity and culture conditions im-
pact the therapeutic efﬁcacy of MSC populations for different disease indications.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Mesenchymal stem cell (MSC)-based therapies are currently being
evaluated in more than 500 clinical trials (https://clinicaltrails.gov) for
the treatment of various skeletal and non-skeletal related disorders. Al-
though some patients have beneﬁted signiﬁcantly by these treatments,
many MSC-based clinical trials have yielded suboptimal outcomes or
failed to meet their primary endpoints of efﬁcacy (Phinney et al.,
2013; Lin and Hogan, 2011). A limiting factor in the development of ef-
ﬁcaciousMSC-based therapies is the fact thatMSCs are ill-deﬁned based
on physical, phenotypic and functional properties. For example, rou-
tinely used methods to isolate MSCs from bone marrow yield popula-
tions that exhibit signiﬁcant heterogeneity in terms of morphologic
features, growth rate, life span, differentiation potential, and potency
in functional-based assays (Phinney, 2007; Wagner and Ho, 2007;
Zhou et al., 2008; Russell et al., 2010;Whitﬁeld et al., 2013). Additional-
ly, few if any established surface markers used to characterize MSCs re-
late phenotype to function thereby making it difﬁcult to determine
whether cell preparations used in translational/clinical studies are of
similar composition and biological activity. Finally, the prevailingherapeutics, A231, The Scripps
iter, FL, USA.
.
. This is an open access article underviewpoint that MSCsmodulate the immune system and promote tissue
regeneration independent of their stem/progenitor properties (Caplan
and Correa, 2011; Bernardo and Fibbe, 2013) has impeded efforts to de-
scribe their functional complexity using established principles of stem
cell biology.
Here we explored the mechanisms that confer different functional
attributes onto MSCs to gain insight at the cellular and molecular level
as to how they achieve such broad-based therapeutic effects. Our results
establish the transcription factor Twist1 as an intrinsic determinant of
intra- and inter-population heterogeneity by regulating multiple path-
ways affecting cell growth, cell cycle progression, DNA replication, cell
surface receptor signaling and survival. Furthermore, we show that
Twist1 is a direct target of ﬁbroblast growth factor (Fgf2) and interferon
gamma (IFN-gamma) action in MSCs, and that alterations in Twist1
levels mediated by exposure to Fgf2, IFN-gamma or via direct genetic
manipulation alters the growth, survival and multi-potency as well as
angiogenic, anti-inﬂammatory and immuno-modulatory activities of
cells in predictable ways. These ﬁndings demonstrate a direct mecha-
nistic link between stem/progenitor and effector functions in MSCs,
and reveal that Twist1-mediated changes in cell function/efﬁcacy can
be modeled via a hierarchical process. Using this information we devel-
oped a CLinical Indications Prediction (CLIP) scale that predicts the ther-
apeutic efﬁcacy of different human MSC donor populations for a given
disease indication based on TWIST1 expression levels, which speciﬁes
the positional identity of cells within the established hierarchy.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Cell Culture
Human MSCs were obtained from bone marrow as previously
described (Russell et al., 2010) and seeded at 500–1000 cells/cm2 in
complete culture media (CCM) consisting of α-MEM with 2 mM L-
glutamine (GIBCO), 17% FBS (HyClone), 100 U/ml penicillin and
100 μg/ml streptomycin. Colony forming unit-ﬁbroblast (CFU-F) con-
tent andmulti-lineage differentiationwas determined as previously de-
scribed (Russell et al., 2010). Cell growth was analyzed using the MTT
Cell Proliferation Assay Kit (Cayman Chemical Company) or by ﬂow cy-
tometric analysis of carboxyﬂuorescein succinimidyl ester (CSFE)-la-
beled cells. Cells were initially seeded at 1000 cells/cm2 for MTT and
CSFE assays and analyseswere conductedwhen cells reached ~50% con-
ﬂuence to ensure log phase growth. MSCs were transfected with small
interfering RNAs (siRNAs) using the inverse transfection protocol
(Invitrogen) and collected at 3 days post-transfection for viability
measures, cell cycle analysis and to harvest RNA and protein, at 7 days
post-transfection for cell proliferation assays, and at 14 days post-
transfection for CFU-F assays. Stained cells were analyzed using an LSR
II Flow Cytometer System (Beckton Dickinson) and FlowJo software
(Tree Star, Inc.).
2.2. Microarray Analysis
An equal amount of RNA was pooled from triplicate experiments
and cDNA prepared following the manufacturer's protocols from the
WT expression kit (4411973, Affymetrix). Biotin-labeled cDNA was
fragmented and hybridized to the Human Gene ST 1.0 microarray
(901086, Affymetrix) and data analysis was performed using Expres-
sion Console analysis software (Affymetrix). These data have been de-
posited in NCBI's Gene Expression Omnibus (GEO) and are accessible
through GEO Series accession number GSE76158 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE76158). Functional proﬁling
ofmicroarray data was performed using g:Proﬁler based on hierarchical
sorting using the best parent ﬁt (Reimand et al., 2011). Unbiased gene
annotation enrichment analysis for the top ﬁve functional clusters of
Twist1 targetswas performed byDAVID analysis using automated func-
tional annotation clustering based on GO Terms of biological processes
(GO_BP_FAT). Gene lists were annotated using the gene accession con-
version tool to ensure accuracy. The individual genes of these ﬁve cate-
gories were then curated for enhanced accuracy by systematic search of
the GeneCards Compendium (http://www.genecards.org), which vali-
dated almost all of the initial genes.
2.3. Mixed Lymphocyte Reactions
Freshly isolated human peripheral blood mono-nuclear cells
(PBMNCs) obtained from OneBlood Florida (http://www.oneblood.
org) were suspended in RPMI-10 media supplemented with 10% fetal
bovine serum (FBS) (Atlanta Biologics), 1× MEM Vitamin solution, 1×
MEM NEAA solution, 1× L-Glut, 0.01 M HEPES, 100 U/ml penicillin,
100 U/ml streptomycin, 1 mM Sodium pyruvate (all from Gibco), and
10 ng/ml IL-2 (Biolegend) and co-cultured with pre-plated MSCs at a
MSC:PBMNC ratio of 1:20. Dynabeads® Human T-Activator CD3/CD28
(Gibco) were added to the co-culture at a bead/PBMNC ratio of 2:1. Cul-
tures were then incubated at 37 °C in 5% CO2 for 5 days after which the
non-adherent PBMNCswere collected and stained using the FITCMouse
Anti-Human Ki-67 Set (556026, BD Pharmingen) according to
manufacturer's instructions. Alternatively, Th1/Th2/Th17 cytokines
were measured in the conditioned media collected 5 days post-co-cul-
ture using the Human Th1/Th2/Th17 CBA Kit (560485, BD Biosciences)
according to manufacturer's instructions. Brieﬂy, 50 μl of cytokine stan-
dards and samples were mixed with 50 μl of mixed capture beads and
phycoerthyrin (PE) detection reagent and incubated for 3 h. Beadswere washed, suspended in 300 μl wash buffer and analyzed by ﬂow
cytometry. Median intensity of PE ﬂuorescence was used to derive con-
centration vs.ﬂuorescence standard curves to determine the concentra-
tion of each cytokine.
2.4. Chip-PCR
MSCs were cultured in media containing 1% formaldehyde to cross-
link protein and DNA and the reaction quenched by adding 1.375M gly-
cine to the culturemedia. The cell monolayer was harvested by scraping
in 1× cold PBS, centrifuged at 1500 rpm for 10 min at 4 °C, incubated in
cell lysis buffer and then the DNA sheared by sonication. Twist1 bound
chromatin was precipitated using an anti-Twist1 antibody (sc-15393,
Santa Cruz Biotechnology) and the Dynabeads® Protein G Immuno-
precipitation kit (Life Technologies). Eluted DNA was puriﬁed using
spin columns (Qiagen) and then used as input in real-time PCR reac-
tions using the primers listed in Table S5.
2.5. TWIST1 Cloning
Genomic DNAwas puriﬁed from humanMCS using the Quick-gDNA
MiniPrep Kit (Zymo Research) according to manufacturer's directions.
TWIST1 was ampliﬁed by polymerase chain reaction using the KOD
HotStart DNA Polymerase (EMD Millipore) with the forward and re-
verse primers 5′-GCCTGCACGGAGGTATAAG-3′ and 5′-GAGGAAATCG
AGGTGGACTG-3′, respectively. Following ampliﬁcation, the product
was blunt ligated into the EcoRV site of pBlueScript II SK+ using T4
DNA Ligase (New England Biolabs). Following sequence and orientation
veriﬁcation, pBlueScript-TWIST1 was digested with XhoI and EcoRI
and the product ligated into the XhoI and EcoRI site of pMSCV-PIG
(Addgene) to generate a TWIST1 retroviral construct (pMSCV-PIG-
Twist1). The latter was co-transfected into HEK-293 cells with pCL-
Ampho using Lipofectamine 2000 (Life Technologies) according to
manufacturer's directions. At 72 h post-transfection supernatant was
collected, passed through a .45 μm syringe ﬁlter, and 4ml of ﬁltered su-
pernatant was combined with 1 ml of fresh MSC media and 4 μg/ml
polybrene and added to MSCs plated at a density of 1000 cells/cm2 in
a 60 mm dish. MSCs were subsequently sorted for GFP expression by
FACS. A pMSCV-PIG vector-only control was generated using the same
method.
2.6. In Vivo Treatments
All animal studies conform to the Guide for the Care and Use of Labo-
ratory Animals (The Nationals Academic Press, Eight Edition) and proto-
cols approved by the Institutional Care and Use Committee of Scripps
Florida. Institutional review board (IRB) approval was obtained for use
of human samples. Bleomycin-induced lung injury was performed as
previously described (Ortiz et al., 2003; Ortiz et al., 2007) except
experiments were conducted using immune-deﬁcient mice (B6.CB17-
Prkdcscid/SzJ, The Jackson Labs) and animals were administered
5 × 105 human MSCs. Where indicated human MSCs were cultured in
Fgf2 (20 ng/ml) supplemented media for 7 days or transfected with a
TWIST1-speciﬁc siRNA.
2.7. Statistical Analyses
Signiﬁcance was estimated by unpaired Student's t test in experi-
ments where comparisons between two groups was warranted. Alter-
natively, signiﬁcance was determined by one-way analysis of variance
(ANOVA) and post-hoc Tukey or Tukey–Kramer tests for equal or un-
equal sample size, respectively. Cell cycle data was ﬁt using theWatson
pragmatic model and correlations were determined using the Pearson's
moment correlation coefﬁcient. Differences between treatment groups
were considered signiﬁcant with a p value of ≤0.05.
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3.1. TWIST1 Levels Predict Intrinsic Differences Between MSC Donor
Populations
It is well-established that MSC populations derived from different
human donors are intrinsically heterogeneous. Therefore, we initial-
ly questioned if donor-to-donor heterogeneity of MSC populations is
informed by Twist1, a potent epithelial-to-mesenchymal transition
inducer, based on recent studies indicating that some proportion of
marrow resident MSCs derive from the neural crest (Morikawa
et al., 2009). Therefore, we quantiﬁed TWIST1 levels in nine
human donor populations that during log phase growth exhibitedFig. 1. TWIST1 levels predict differences in growth rate and CFU-F activity between humanMSC
1000 cells/cm2, cultured for 7 days to ensure log phase growth, and then analyzed by MTT assa
(b) Growth rate of nine different human MSC donor populations. MSCs were cultured as in
experiments performed in triplicate. (c) CFU-F activity of nine different human MSC donor p
the number of CFU-Fs determined by counting. Plotted data are mean ± SD from experim
determined by ﬂow cytometry in nine human MSC donor populations from (a). MSCs harves
(e) TWIST1/GAPDH mRNA levels as determined by qPCR in nine different human MSC don
quadruplicate and repeated twice. (f) Scatter plot between MSC viability data (a) and TW
coefﬁcient. (g) Scatter plot between MSC growth data (b) and TWIST1/GAPDH mRNA levels
between CFU-F data (c) and TWIST1/GAPDHmRNA levels (e) where (r) is the Pearson's prod
ANOVA and Tukey post-hoc analysis for (a–c) and (e).signiﬁcant differences in viability and growth rate as quantiﬁed by
MTT assay (Fig. 1a) and cell counting (Fig. 1b), respectively. Colony
forming unit-ﬁbroblast (CFU-F) activity, a measure of progenitor
cell frequency, also varied signiﬁcantly between these populations.
(Fig. 1c). Expressed levels of 20 different markers commonly used
to phenotype MSCs did not predict inter-population differences in
these activities (Fig. 1d and Table S1). However, normalized
TWIST1 mRNA levels, which varied signiﬁcantly between popula-
tions (Fig. 1e), signiﬁcantly correlated with measures of cell viability
(Fig. 1f), cell growth (Fig. 1g) and CFU-F activity (Fig. 1h). The nature
of this correlation was robust since a comparison between TWIST1
raw Ct values and cell viability, growth, and CFU-F activity were
also signiﬁcantly correlated (Fig. Fig. S1a–d).donors. (a) Viability of nine different humanMSC donor populations. MSCswere plated at
y. Plotted data are mean ± SD from experiments performed twice with 8 replicates each.
(a) and total cell number determined by counting. Plotted data are mean ± SD from
opulations. MSCs (100 cells/55 cm2) were plated in triplicate, cultured for 14 days, then
ents performed in triplicate. (d) Expressed levels of the indicated surface epitopes as
ted at sub conﬂuent density (b70%) were used for analysis. Plotted data are mean ± SD.
or populations from (a). Plotted data are mean ± SD from experiments performed in
IST1/GAPDH mRNA levels (e) where (r) is the Pearson's product moment correlation
(e) where (r) is the Pearson's product moment correlation coefﬁcient. (h) Scatter plot
uct moment correlation coefﬁcient. *p b 0.05, **p b 0.01 as compared to 99L by one-way
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inhibited TWIST1 expression using a small interfering RNA (siRNA)
in a representative donor population that expressed intermediate
TWIST1 levels (7089L) (Fig. 2a). Quantitative real-time PCR (qPCR)
analysis of siRNA-transfected MSCs indicated that TWIST1 mRNA
levels remained repressed up to seven days post-transfection (Fig. 2b).
As anticipated based on this result, TWIST1 silencing signiﬁcantly
inhibited cell growth and viability as determined by counting
(Fig. 2c), MTT assay (Fig. 2d) and ﬂow cytometric analysis of 6-
Carboxyﬂuorescein succinimidyl ester (CSFE)-labeled cells (Fig. 2e). ItFig. 2. SiRNA targeting of TWIST1 negatively impacts MSC growth and survival. (a) Immunoblo
(Scr) or TWIST1-speciﬁc (TWIST1) siRNA. Data are from cell extracts prepared 3 days post-transf
fection as determined by qPCR. Plotted data are mean± SD from experiments performed in qu
cultured for 7 days after siRNA transfection to ensure log phase growth, then cell number was d
licate and repeated twice. (d) Effect of siRNAs on MSC viability. MSCs were cultured as in (c) th
with six replicates each. (e) Effect of siRNAs on MSC growth as determined by CSFE-labeling. A
transfection then analyzed by ﬂow cytometry. (f) Effect of siRNAs on CFU-F activity. Following s
mean ± SD from experiments performed in triplicate and repeated once. (g) Effect of siRNAs o
cultured for 3 days prior to staining for senescence associated β-galactosidase activity. Data are
optosis. Following siRNA transfection MSCswere plated at 1000 cells/cm2, cultured for 3 days p
etry. (i) Immunoblot analysis of cell cycle regulators in cell lysates fromMSCsplated at 1000 cell
status. Following siRNA transfection MSCs were plated at 1000 cells/cm2, expanded 3 days the
(upper) and total and phosphor-ERK1/2 (lower) in cell extracts prepared from MSCs at 3 day
cells. **p b 0.01, #p b 0.005, ++p b 0.0005 as compared to scrambled by Student's t test for (balso signiﬁcantly reduced CFU-F activity (Fig. 2f) and residual CFU-
Fs that did emerge were smaller in size than those from scrambled
siRNA transfected cells (not shown). SiRNA targeting of TWIST1
also increased the percentage of senescent (Fig. 2g) and apoptotic
cells (Fig. 2h) in populations. TWIST1 inhibition yielded similar bio-
logical responses in multiple donor populations (not shown) where-
as siRNA targeting of TWIST2 had no signiﬁcant effect on cell growth,
CFU-F activity, senescence or apoptosis (Fig. 2c–h).
To identify Twist1 targets responsible for these biological effects we
performed micro-array analysis, which identiﬁed 216 transcripts upt analysis of Twist1 levels in native MSCs (Control) or MSCs transfected with a scrambled
ection. (b) Effect of siRNAs on TWIST1/GAPDHmRNA levels at 3 days and 7 days post-trans-
adruplicate. (c) Effect of siRNAs onMSC proliferation. MSCs were plated at 1000 cells/cm2,
etermined by counting. Plotted data are mean ± SD from experiments performed in trip-
en analyzed by MTT assay. Plotted data are mean ± SD from experiments repeated twice
ssays were conducted as described in (c) except that cells were stained with CSFE prior to
iRNA transfection MSCs were plated at 100 cells/55cm2 and cultured for 14 days. Data are
n MSC senescence. Following siRNA transfection MSCs were plated at 5000 cells/cm2 and
mean ± SD from experiments performed in triplicate. (h) Effect of siRNAs on cellular ap-
rior, then stained with Annexin V and propidium iodide (PI) and analyzed by ﬂow cytom-
s/cm2 at 3 dayspost-transfectionwith the indicated siRNAs. (j) Effect of siRNAs on cell cycle
n stained with DAPI and analyzed by ﬂow cytometry. (k) Immunoblot analysis of RASA4
s post-transfection with the indicated siRNAs. Control represents non-transfected native
–d, f, g).
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lowing siRNA targeting of TWIST1 (Table S2). Unbiased analysis of the
gene expression data, which was deposited in NCBI's GEO repository
[GSE76158] revealed that Twist1 targetsmapped to critical nodes with-
in multiple gene regulatory networks (Fig. S2) controlling cell surface
receptor-linked signal transduction, cell cycle progression, cell division,
DNAmetabolic processes, DNA replication,DNA repair, and homeostatic
processes (Fig. S3). Consistent with these results, siRNA targeting of
TWIST1 resulted in increased P21 and decreased P53, Ccnd3, Cdk2 and
Cdk4 protein expression (Fig. 2i and Fig. S1e), which manifested in
changes in cell cycle progression. For example, populations' transfected
with a TWIST1-speciﬁc siRNA contained signiﬁcantly more cells in G1
phase and fewer cells in S phase as compared to scrambled siRNA
transfected or non-transfected populations (Fig. 2j). SiRNA targeting of
TWIST1 also induced expression of Rasa4 (Fig. 2k and Fig. S1f), and
siRNA targeting of RASA4 resulted in increased Cdk2, Cdk4, and Ccnd3
expression (Fig. 2i and Fig. S1e) and elevated Erk1/2 activation (Fig.
2k and Fig. S1f) consistent with its role as an inhibitor of Ras-Mapk sig-
naling. SiRNA targeting of SPRY4, an inhibitor of Fgf-induced Erk signal-
ing that served as a positive control, also increased p-Erk1/2 levels (Fig.
2k and Fig. S1f).Fig. 3. Twist1 confers multi-potency onto MSCs. (a) Tri-lineage differentiation potential of ﬁve
number. (b) Scatter plots of TWIST1/GAPDHmRNA levels vs. chondrogenic, osteogenic and adip
correlation coefﬁcient. (c) TWIST1/GAPDHmRNA levels as determined by qPCR in tri-potent c
(d) Effect of siRNAs on gene expression as determined by qPCR in MSCs. Values were determ
transfection MSCs were plated at 5000 cells/cm2 and expanded for 3 days. Data are mean
differentiation in MSCs at 7 days post-induction for adipogenesis and at least 21 days post
stained with Nile Red (adipogenesis), Alizarin Red S (osteogenesis) or Toluidine blue (ch
compared to scrambled by Student's t test for (d, e).3.2. TWIST1 Levels Correlate with Tri-lineage Differentiation Potential and
Maintain Cells in an Uncommitted State
To assess effects on multi-potency we quantiﬁed TWIST1 levels in
ﬁve MSC donor populations that exhibited quantitative differences in
tri-lineage differentiation (Fig. 3a) and found that normalized expres-
sion levels of this mRNA correlated with adipogenic, chondrogenic
and osteogenic potential (Fig. 3b). To assess effects at the single cell
level, we generated clonally-derived populations and determined their
capacity for tri-lineage differentiation by clone splitting (Russell et al.,
2010). As shown in Fig. 3c, normalized TWIST1mRNA levels were signif-
icantly higher in clones capable of tri-lineage differentiation as com-
pared to bi-potent clones. As anticipated based on these results, siRNA
targeting of TWIST1 signiﬁcantly induced expression of key regulators
of cell differentiation including RUNX2, PPAR-γ, SOX4, BMP4, and
GDF15 (Fig. 3d) (Brun et al., 1996; Hammarstedt et al., 2013; Kim
et al., 1999; Komori et al., 1997; Nissen-Meyer et al., 2007), and also sig-
niﬁcantly augmented that ability of cells to undergo tri-lineage differen-
tiation in response to the appropriate stimuli (Fig. 3e). However, siRNA
targeting of TWIST1 did not induce spontaneous differentiation in the
absence of stimuli (not shown). These ﬁndings implicate Twist1 inMSC donor populations relative to an un-induced control after normalization to total cell
ogenic potential of MSCs as determined in (a) where (r) is the Pearson's product moment
lones (N = 10) and bi-potent (N = 6) human MSC clones. *p b 0.05 by Student's t test.
ined using the relative Ct method with GAPDH as an internal control. Following siRNA
± SD for experiments performed in quadruplicate. (e) Effect of siRNAs on tri-lineage
-induction for osteogenesis and chondrogenesis. Photomicrographs are of monolayers
ondrogenesis, false color image). *p b 0.05, **p b 0.01, +p b 0.001, ++p b 0.0005 as
67S.V. Boregowda et al. / EBioMedicine 4 (2016) 62–73maintenance of the multi-progenitor state by simultaneously stimulat-
ing cell growth and survival and repressing pathways that induce com-
petence to respond to differentiation inducing stimuli.
3.3. TWIST1 is a Target of Fgf2 and Confers a Pro-angiogenic Phenotype
Onto MSCs
Previous studies have shown that Fgf2 promotes growth and self-
renewal of MSCs (Ahn et al., 2009; Tsutsumi et al., 2001; Di MaggioFig. 4. Twist1 is a target of Fgf2 and confers a pro-angiogenic phenotype onto MSCs. (a) Effect
Valueswere determined using the relative Ctmethod with GAPDH as an internal control. (b) Sc
(r) is the Pearson's product moment correlation coefﬁcient. Data are from MSC populations in
(r) is the Pearson's product moment correlation coefﬁcient. Data are fromMSC donor populatio
and cell viability (MTT assay, right panel)where (r) is the Pearson's productmoment correlation
expression levels as determined by qPCR inMSCs transfected with a scrambled (Scr) or Fgfr2III
MSC viability as measured by MTT assay. MSCs were plated at 1000 cells/cm2 and cultured fo
experiments performed in triplicate and repeated twice. (g) ELISA showing effect of siRNAs
ELISA was performed on fresh media added 48 h following siRNA transfection or 24 h followi
Ccl2. (h) Growth of HAECs cultured in HAEC growth media alone or a mixture (1:1) of HAE
with siRNAs or pre-treated with Fgf2 (20 ng/ml), IFN-gamma (50 ng/ml) and IL-6 (10 ng/ml).
MSC conditionedmedia onHUVEC tube formation. HUVECs plated onmatri-gelwere cultured in
MSCs transfected with siRNAs or pre-treated with Fgf2 (20 ng/ml), IFN-gamma (50 ng/ml) and
analysis software. Plotteddata aremean±SD fromexperiments performedwith in triplicate. *p
for (a, e, f). *p b 0.05, **p b 0.01 compared to control (g), No CM (h) and Scrambled siRNA (i) by
between experimental groups.et al., 2012). Consistent with these studies, we found that siRNA
targeting of TWIST1 induced expression of FGF2, FGFR1, FGFR3 and
FGFR4 but suppressed expression of FGFR2IIIc (Fig. 4a) and that culture
of MSCs in Fgf2-supplemented media induced Twist1 protein accumu-
lation (Fig. S4a). We further observed a positive correlation between
normalized FGFR2IIIc and TWIST1mRNA levels in different MSC donor
populations (Fig. 4b) and although this correlation did not reach statis-
tical signiﬁcance the correlation between FGFR2IIIc and TWIST1 Ct
values was statistically signiﬁcant (Fig. 4c). Additionally, normalizedof siRNAs on gene expression as determined by qPCR in MSCs at 3 days post-transfection.
atter plot of FGFR2IIIc/GAPDH vs. TWIST1/GAPDHmRNA levels as determined by PCRwhere
Fig. 1. (c) Scatter plot of FGFR2IIIc vs. TWIST1 raw Ct values as determined by qPCR where
ns in Fig. 1. (d) Scatter plot of FGFR2IIIc/GAPDHmRNA levels vs. CFU-F activity (left panel)
coefﬁcient. Data are fromMSCdonor populations in Fig. 1. (e) FGFR2IIIc and TWIST1mRNA
c-speciﬁc siRNA. Assays were conducted at 3 days post-transfection. (f) Effect of siRNAs on
r 7 days after siRNA transfection to ensure log phase growth. Data are mean ± SD from
or pre-treatment with Fgf2 (20 ng/ml) or IL-6 (10 ng/ml) on secretion of Ccl2 by MSCs.
ng mitogen pretreatment. Cells were cultured an additional 48 h before quantiﬁcation of
C growth media and conditioned media from native or ﬁxed MSCs or MSCs transfected
Plotted data are mean ± SD from experiments performed with six replicates. (i) Effect of
growthmedia (GM), serum freemedia (SFM) or conditionedmedia fromnativeMSCs and
IL-6 (10 ng/ml) for 12 h. Length of endothelial tubules was then determined using image
b 0.05, #pb 0.005,+p b 0.001,++p b 0.0005 as compared to scrambled byStudent's t test
on one-way ANOVA and post-hoc Tukey test for (g–i). Bars highlight signiﬁcant differences
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growth/viability of different MSC donor populations (Fig. 4d) but we
failed to detect any correlation between TWIST1, cell growth or CFU-F
activity and FGFR1, FGFR3, FGFR4 or AXL expression (not shown). As an-
ticipated based on this result, siRNA targeting of FGFR2IIIc also signiﬁ-
cantly decrease FGFR2IIIc and TWIST1 expression in MSCs (Fig. 4e) and
signiﬁcantly inhibited cell viability as determined by MTT assay (Fig.
4f). The fact that siRNA targeting of FGFR2IIIc produced similar effects
in MSCs as that of TWIST1 indicates that Twist1 is positively regulated
by an Fgf2–Fgfr2IIIc signaling axis.
Through a process that involves vascular remodeling, MSCs are
capable of generating ectopically a miniature bone organ that con-
tains hematopoiesis-competent sinusoids (Friedenstein et al., 1968;
Sacchetti et al., 2007). Since Twist1 is also implicated in regulating
vascularization during development and tumorigenesis (Rodrigues
et al., 2008; Hu et al., 2008) we questioned if this protein confers a
pro-angiogenic phenotype. Interrogation of our micro-array data re-
vealed that siRNA targeting of TWIST1 repressed expression of the
pro-angiogenins CLC2, CXCL12, FGF5, VEGFC and CYR61 and induced
mRNAs encoding proteins with angio-static activity, such as TIMPs
1–4, ADAMTS2 and CTGF (Fig. S4b). This result is consistent with a
previous study demonstrating that Twist1 induces Ccl2 expression
in mammary epithelial cells although the mechanism responsible
for this effect has not been explored (Li et al., 2003). A bioinformatics
searched identiﬁed several consensus E-box motifs in the Ccl2
promoter (Table S3) andwe conﬁrmed by ChIP that Twist1 was asso-
ciated with this promoter (Fig. Fig. S4c). Our micro-array data
further demonstrated that treatment of MSCs with Fgf2 induced ex-
pression of the pro-angiogenins VEGFC, CYR61 and FGF5 and
inhibited expression of TIMP1, TIMP2 and CTGF, which block angio-
genesis (Fig. S4d). Enzyme-linked immunosorbent assay (ELISA)
conﬁrmed that siRNA targeting of TWIST1 and FGFR2IIIc inhibited
whereas pre-treatment with Fgf2 stimulated Ccl2 secretion from
MSCs (Fig. 4g). Next, we collected conditioned media from native
MSCs or MSCs pre-treated with Fgf2 and IL-6 or transfected with a
TWIST1-speciﬁc and scrambled siRNA, then assayed its ability to sup-
port the growth of primary human aortic endothelial cells (HAECs).
As shown in Fig. 4h, conditioned media from native MSCs pre-
treated with or without IL6 yielded signiﬁcant increases in HEAC sur-
vival as compared to that from ﬁxed MSCs or the cell free control.
Moreover, conditioned media from Fgf2 pre-treated MSCs was supe-
rior to that of native MSCs in supporting HAEC survival whereas that
from MSCs transfected with a TWIST1-speciﬁc siRNA or pre-treated
with IFN-gamma offered no signiﬁcant beneﬁt as compared to the
cell free control. We also assayed the ability of MSC conditioned
media to support tube formation by human umbilical vein endothe-
lial cells (HUVECS) using serum free media (SFM) or growth factor
supplementedmedia (GM) as negative and positive controls, respec-
tively. As shown in Fig. 4i, conditioned media from native MSCs and
MSCs transfected with a scrambled siRNA or pre-treated with IL6
were not as effective as GM in supporting tube formation but were
signiﬁcantly better than SFM. Moreover, tube formation was signiﬁ-
cant greater in conditioned media from Fgf2 pre-treated MSCs and
signiﬁcantly less from TWIST1 siRNA transfected or IFN-gamma
pre-treated cells as compared to native MSCs. Collectively, these
studies demonstrate that Fgf2 induces a pro-angiogenic phenotype
onto MSCs via a Twist1-dependent mechanism.
3.4. TWIST1 Regulates Cytokine and Immuno-modulatory Effector Protein
Expression and is a Target of IFN-Gamma
MSCs also exhibit potent anti-inﬂammatory and immuno-modula-
tory activities but a role for Twist1 in these processes has not been de-
scribed. We found that siRNA targeting of TWIST1 signiﬁcantly
induced expression of IL1-α, IL1-β, IL1RN, IL18, TNF and TSG6 but
inhibited expression of IL6 (Fig. 5a), consistent with its ability torepressesNF-kB activity by binding to RelA (Sosic et al., 2003). However,
multi-plex ELISA ofMSC conditionedmedia failed to detect IL-1α, IL-1β,
and Tnf indicating that native MSCs do not secrete these pro-
inﬂammatory cytokines. We did detect secreted levels of Il1rn, IL-6
and IL-8. Moreover, siRNA targeting of TWIST1 signiﬁcantly increased
Il1rn and inhibited IL-6 secretion, whereas culture of MSCs in Fgf2 sig-
niﬁcantly enhanced secretion of all three cytokines (Fig. 5b). Fgf2-
mediated increases in IL-6 likely result from increased Twist1 expres-
sion since this effect was abolished following siRNA targeting of this
gene (Fig. S4e). SiRNA targeting of TWIST1 also abolished Fgf2-induced
increases in secretion of Ccl2 (Fig. S4f) consistent with our ChIP data
but not that of IL-8 (Fig. S4g). The latter likely results from increased ac-
tivator protein 1 (AP1) activity since this protein is a target of Fgf2 and
stimulates IL-8 transcription (Li et al., 2003).
We also found that transcripts encoding proteins that contribute to
the immuno-modulatory activity of MSCs including indoleamine 2, 3-
dioxygenase (Ido1), heme oxygenase 1 (Hmox1), prostaglandin-
endoperoxidase synthase 2 (Ptgs2/Cox2), prostaglandin E synthase
(Ptges) and colony stimulating factor 1 (Csf1)were also induced follow-
ing siRNA targeting of TWIST1 (Fig. 5c). Consistent with these results,
MSCs transfected with a TWIST1-speciﬁc vs. scrambled siRNA secreted
signiﬁcantly higher levels of prostaglandin-E2 (Pge2) (Fig. 5d) and
expressed higher levels of Ido1 protein (Fig. 5e). Interrogation of the
IDO1 promoter revealed several consensus E-box motifs (Table S3)
and ChIP analysis conﬁrmed that Twist1 associated with this promoter
(Fig. 5f). Therefore, Twist1 activates CCL2 and represses IDO1 transcrip-
tion. Difference in Twist1 activity at these promoters is likely inﬂuenced
by distinct basic regionDNA conformations and choice of protein dimer-
ization partners (Kophengnavong et al., 2000). We did not detect bind-
ing of Twist1 to the HMOX1 promoter, which lacked E-box motifs,
indicating that Twist1 regulates HMOX1 expression indirectly (not
shown).
IFN-gamma strongly induces Ido1 in MSCs wherein it functions as a
T-cell inhibitory effector pathway (Meisel et al., 2004; Krampera et al.,
2006). Therefore, we questioned if IFN-gamma modulates Ido1 expres-
sion via Twist1. Western blot conﬁrmed that pre-treatment of MSCs for
24 h with IFN-gamma strongly repressed Twist1 and induced Ido1 ex-
pression whereas treatment with IL-6 had little effect on either protein
(Fig. 5g). Consistent with these results, the ability of IFN-gamma to in-
duce IDO1 expression was signiﬁcantly inhibited in MSCs engineered
to over express Twist1 by retroviral transduction (Fig. 5h). Moreover,
IFN-gammapre-treatment repressed TWIST1 expression but signiﬁcant-
ly induced that of PTGS, PTGES, and IL1RN (Fig. S5a). It also suppressed
MSC growth (Fig. 5i and Fig. S5b), CFU-F activity (Fig. 5j) and Rpl23a,
Cdk2 and Cdk4 expression (Fig. 5k) thereby mimicking effects seen fol-
lowing siRNA targeting of TWIST1. Growth inhibition by IFN-gamma
was abrogated in MSCs treated with the Ido1 inhibitor CAY10581 and
therefore was dependent upon induced Ido1 activity (Fig. 5l). MSCs
treated with IFN-gamma also exhibited signiﬁcantly reduced angiogen-
ic activity (Fig. 4h and i) while MSCs cultured in Fgf2 exhibited en-
hanced growth, CFU-F activity, and increased expression of Ccnd3,
Cdk2 and Cdk4 (Fig. 5i–k).
IFN-gamma and Fgf2 also produced disparate effects on stimulus
driven cellular differentiation, which reﬂects their broader effects on
cell signaling pathways and gene expression as compared to Twist1 in-
hibition alone. For example, IFN-gamma pre-treatment augmented
adipogenic and suppressed osteogenic differentiation in response to
the appropriate stimuli to signiﬁcant extents as reported previously
(Liu et al., 2011; Vidal et al., 2012) while Fgf2 pre-treatment inhibited
adipogenic differentiation and resulted in a slight increase in matrix
mineralization over a time course of osteogenic differentiation
(Fig. S5c and d). The latter is consistent with studies indicating that
Fgf2 lowers the phosphate threshold for mineralization by directly in-
ducing expression of the calcium binding proteins bone sialoprotein
and osteocalcin (Shimizu-Sasaki et al., 2001; Nauman et al., 2003;
Xiao et al., 2002).
Fig. 5. Twist1 modulates cytokine and immuno-modulatory effector protein expression in MSCs. (a) Effect of siRNAs on gene expression as determined by qPCR in MSCs at 3 days post-
transfection. Values were determined by the relative Ct methods using GAPDH as an internal control. Plotted data are mean ± SD from experiments performed in quadruplicate.
(b) Luminex assay showing levels of the indicated cytokines in MSC conditioned media. Plotted data are mean ± SD from experiments performed in triplicate. (c) Effect of siRNAs on
gene expression as determined by qPCR in MSCs at 3 days post-transfection. Plotted data are mean ± SD from experiments performed in quadruplicate. (d) Effect of siRNAs on Pge2
secretion in MSCs. Plotted data are mean ± SD normalized to total cell number. (e) Immunoblot assay and corresponding density plot showing effect of siRNAs on Ido1 expression in
cell extracts prepared from MSCs at 3 days post-transfection. (f) ChIP analysis showing pull down of IDO1 promoter sequences using a Twist1 or Pol II (positive control) antibody from
cell extracts prepared from MSCs. (g) Immunoblot analysis of Ido1 and Twist1 levels in cell extracts from MSCs at 24 h post-treatment with IFN-gamma (50 ng/ml) or IL-6 (10 ng/ml).
(h) TWIST1/GAPDH mRNA levels as determined by qPCR in MSCs transduced with an empty retroviral vector or one encoding a full length TWIST1 cDNA (left). Insert represents
immunoblot analysis of Twist1 in cell extracts prepared from transfected MSCs. IDO1/GAPDHmRNA levels as determined by qPCR in transduced MSCs at 24 h post-treatment with IFN-
gamma (50 ng/ml) (right panel). Plotted data are mean ± SD of experiments performed in triplicate. (i) Effect of Fgf2 (20 ng/ml), IFN-gamma (50 ng/ml), and IL-6 (10 ng/ml) pre-
treatment on MSC growth quantiﬁed by ﬂow cytometric analysis of CSFE-stained cells. Plotted data are mean ± SD. (j) Effect of Fgf2 (20 ng/ml), IFN-gamma (50 ng/ml), and IL-6
(10 ng/ml) pre-treatment on CFU-F activity. Graph illustrates all quantiﬁed CFU-Fs and those N10 mm in diameter after 14 days of culture. Plotted data are mean ± SD of experiments
repeated twice and performed in triplicate. **p b 0.01 compared to Fgf2 treatment group by one-way ANOVA and post-hoc Tukey test. (k) Immunoblot analysis of Rpl23a, Ccnd3,
Cdk2, and Cdk4 in cell extracts from MSCs (Cont) or MSCs pre-treated for 24 h with Fgf2 (20 ng/ml), IFN-gamma (50 ng/ml) and IL-6 (10 ng/ml). (l) Effect of IFN-gamma (50 ng/ml)
and the Ido1 inhibitor CAY10581 (100 nM) on MSC viability as determined by MTT assay at 24 h post-treatment. Plotted data are mean ± SD of experiments performed in
quadruplicate. *p b 0.05, **p b 0.01, #p b 0.005, +p b 0.001, ++p b 0.0005 compared to scrambled (a–d), CCM (b, i), Cont Ab (f), vector (h), and DMSO (l) by Student's t test.
69S.V. Boregowda et al. / EBioMedicine 4 (2016) 62–733.5. Perturbation of TWIST1 Levels Yields Predictable Changes in the Thera-
peutic Efﬁcacy of MSC in Cell-based Assays and In Vivo
We next determined whether perturbation of Twist1 levels altered
the ability of MSCs to suppress proliferation of CD3+ T cells following
antibody-mediated activation in a mixed lymphocyte reaction in vitro.
Addition of ﬁxed or native MSCs signiﬁcantly stimulated and repressed,
respectively, CD3+ T cell proliferation as compared to cultures contain-
ing no MSCs (Fig. 6a). Moreover, MSCs transfected with a TWIST1-
speciﬁc siRNA suppressed T cell proliferation to a signiﬁcantly greater
extent than compared to native or scrambled siRNA transfected cells,and IFN-gamma pre-treated cells inhibited T cell proliferation to an
even greater extent than those transfected with a TWIST1-speciﬁc
siRNA. In separate experiments we showed that MSC mediated inhibi-
tion of T cell proliferation following siRNA targeting of TWIST1 or IFN-
gamma pre-treatment was largely reversed by the Ido1 inhibitor
CAY10581 (Fig. S5e). In contrast, MSCs pre-treated with Fgf2 or IL-6
were no more effective in suppressing T cell proliferation as compared
to native MSCs. Next we employed multiplex bead arrays to quantify
changes in Th1, Th2, and Th17 cytokine secretion by peripheral blood
mononuclear cells (PBMNCs) in these mixed lymphocyte reactions. As
shown in Fig. 6b, native MSCs suppressed Tnf and IL-4 and stimulated
Fig. 6. Twist1 levels predict MSC potency in vitro and in vivo. (a) Dot plots of ﬂow cytometric data showing the proportion of CD3 and Ki67 expressing PBMNCs in mixed lymphocyte
reactions. PBMNCs were stimulated with anti-CD3 and anti-CD28 antibodies then continuously cultured for 5 days in the absence or presence of siRNA-transfected or Fgf2 (20 ng/ml),
IFN-gamma (50 ng/ml) and IL-6 (10 ng/ml) pre-treated MSCs. Fixed MSCs and PBMNCs cultured without MSCs (cell free) were used as controls. Bar graph illustrates the ratio of
Ki67+/Ki67− CD3+ T cells under each condition. **p b 0.01 as compared to scrambled by one-way ANOVA and post-hoc Tukey test. Bars represent signiﬁcant differences between
experimental groups. (b) Cytometric bead array showing secreted levels of Th1, Th2, and Th17 cytokines by PBMNCs in mixed lymphocyte reactions from (a). *p b 0.05, **p b 0.01 vs.
control; +p b 0.05, ++p b 0.01 Fgf2 vs. TWIST1 siRNA, IFN-gamma, and IL-6; #p b 0.05, ##p b 0.01 TWIST1 siRNA vs. IFN-gamma by one-way ANOVA and post-hoc Tukey test.
(c) Change in body weight (%) in mice at 7 days post-treatment for each indicated experimental group (N = 6–10 mice per group repeated twice). BLM, bleomycin. (d) Total cell
counts in BAL at 7 days post-treatment from animals in (c). BLM, bleomycin. (e) IL6 expression levels as determined by qPCR in lung parenchyma from animals in (c) at 7 days post-
treatment. BLM, bleomycin. (f) TWIST1/GAPDH mRNA levels as determined by q PCR in MSC donor populations 7075L and 7089L. *p b 0.05 by Student's t test. (g) Change in body
weight (%) at 7 days post-treatment for each indicated experimental group (N = 6–10, repeated twice). BLM, bleomycin. (h) Total cell counts in BAL at 7 days post-treatment for
animals in (g). BLM, bleomycin. *p b 0.05, **p b 0.01 vs. saline based on one-way ANOVA and post-hoc Tukey–Kramer test for (c–e, g, h). Bars indicate signiﬁcant differences between
treatment groups.
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occur during transition from an acute to chronic inﬂammatory state
(Lawrence and Gilroy, 2007) and may explain whyMSCs are therapeu-
tically efﬁcacious in models of acute tissue injury. Alternatively, MSCs
pre-treated with IFN-gamma or transfected with a TWIST1-speciﬁc
siRNA inhibited expression of Th1 cytokines, did not induce IL-17A,
and stimulated IL-4 and IL-10 secretion to varying degrees, which is
consistent with a Th2 response. Importantly, ﬂow cytometric analysis
indicated that siRNA targeting of TWIST1 did not signiﬁcantly alter the
expression of co-stimulatory molecules on MSCs (Table S4). Therefore,
down regulation of Twist1 enhances immuno-suppressive activity
without affecting the immunogenicity of MSCs.
To ascertainwhether perturbation of Twist1 levels altersMSCpoten-
cy in vivo, we employed a bleomycin (BLM)-induced acute lung injury
model based on published studies showing MSCs are highly protective
in this model (Ortiz et al., 2003; Ortiz et al., 2007). This model employs
immuno-deﬁcient mice as a means to accommodate humanMSC xeno-
grafts and therefore evaluates effects on innate immune cell function
and inﬂammation but not adaptive immunity. Herein, intra-tracheal ad-
ministration of bleomycin induced signiﬁcant weight loss in mice by
7 days post-treatment as compared to saline treated controls (Fig. 6c),which correlatedwith a signiﬁcant increase in the number of inﬁltrating
monocytes and neutrophils in bronchoalveolar lavage (BAL) (Fig. 6d)
and signiﬁcantly elevated IL-6 gene expression in lung parenchyma,
which serve as indicators of lung inﬂammation (O'Mahony et al.,
2012) (Fig. 6e). Alternatively, animals infused with naïve MSCs
(7089L) at the time of lung injury exhibited only modest weight loss
as compared to bleomycin treated animals, which reﬂected reduced air-
way inﬂammation based on signiﬁcantly lower BAL cell counts and re-
duced IL-6 expression, while the same MSCs pre-treated with Fgf2
afforded no protection against the injurious effects of bleomycin (Fig.
6c–e). Next, we compared the potency of 7089L to that of 7075L,
which expressed signiﬁcantly higher levels of TWIST1 (Fig. 6f). As antic-
ipated, MSCs from donor 7075L were signiﬁcantly less effective in
protecting mice against bleomycin-induced injury based on the extent
of weight loss by 7 days post-treatment (Fig. 6g) and the cellularity of
BAL (Fig. 6h). Lastly, we asked whether the potency of donor 7089L
could be improved by transfecting cells with a TWIST1-speciﬁc siRNA
prior to infusion into animals. The transfected cells did not afford signif-
icantly enhanced protection to mice based on body weight assessment
or BAL cell count but in some casesweremore potent in suppressing cy-
tokine gene activation in lung tissue (not shown). Although we did not
Fig. 7. Clinical Indication Prediction (CLIP) scale. Illustrated is a scale that predicts the
therapeutic efﬁcacy of a given MSC donor population based on TWIST1 expression levels.
MSC donor populations expressing high TWIST1 levels are predicted to be beneﬁcial in
treating diseases where angiogenesis is warranted, such as stroke and limb ischemia. In
contrast, low TWIST1 expressing populations are predicted to be beneﬁcial in treating
inﬂammatory and immune-related disorders, such as acute tissue or organ injury and
graft vs. host disease. Importantly, the therapeutic efﬁcacy of the population can also be
altered by manipulating TWIST1 levels through genetic manipulation or exposure of cells
to Fgf2 and IFN-gamma. However, these manipulations also signiﬁcantly impact cell
growth, survival and differentiation potential.
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employed immuno-deﬁcient mice, other groups have established that
IFN-gamma priming augments the immuno-modulatory activity of
MSCs in vivo (Sivanathan et al., 2014), which our data indicate occurs,
in part, by repression of Twist1 expression.
4. Discussion
Results presented herein reconcile several critical aspects of MSC bi-
ology that existing paradigms have not resolved. For example, our ﬁnd-
ings establish a direct mechanistic link between stem/progenitor and
effector functions in MSCs, which according to current dogma are
unrelated. They also extend in a meaningful way the known functions
of Twist1, which despite its important role in tumorigenesis is
understudied in MSCs. For example, Twist1 has been reported to sup-
press osteo/chondro differentiation, stimulate adipogenesis, and inhibit
cellular senescence via Ezh2-mediated suppression of p16 (Isenmann
et al., 2009; Hemming et al., 2013; Cakouros et al., 2012) in MSCs. Our
studies indicate that Twist1 is indispensable for MSC maintenance as
siRNA targeting of this transcript alters multiple pathways affecting
cell growth, replication, survival, multi-potency, and paracrine signal-
ing. Previous groups have interrogated Twist1 function by over express-
ing the protein in MSCs, which may explain differences between
previously published studies and those reported here. Our data also in-
dicate that acquisition by MSCs of different functional traits can be
modeled at the population level by a hierarchical process (see Graphic
Abstract). For example, we provide evidence that high Twist1 express-
ing cells are characterized by rapid growth, high CFU-F activity, a low in-
trinsic level of apoptosis and a pro-angiogenic phenotype, which is
consistent with the characterization of naïve MSCs as marrow resident
pericytes (Crisan et al., 2008). We further demonstrate that Twist1
down regulation confers onto cells anti-inﬂammatory and immuno-
modulatory activities at the expense of angiogenic activity, and also in-
duces competence to undergo stimulus driven tri-lineage differentia-
tion. These ﬁndings expand in a meaningful way the hierarchy of MSC
lineage determination proposed by Caplan (1994) and conﬁrmed by
others (Muraglia et al., 2000; Sarugaser et al., 2009; Russell et al.,
2010; Lee et al., 2010) by superimposing onto it various effector func-
tions that confer therapeutic potency onto MSCs. Consequently, this re-
vised hierarchy provides a unifying framework to model the functional
complexity of populations, predict differences in the therapeutic efﬁca-
cy between donors, and understand how responses to extrinsic factors
alter cell fate and function.
Although hypothesis driven studies that link progenitor and effector
functions are lacking, a careful review of the literature provides an im-
plicit link between these processes. For example, most studies that
pre-condition MSCs with Fgf2 or Vegf to enhance their angiogenic po-
tential report positive effects on cell growth, survival, and CFU-F activity
while studies that employ pre-conditioning to enhance immuno-
modulatory activity are devoid of such claims (unpublished data).
Moreover, studies have shown that differentiation of MSCs to the oste-
oblast lineage results in a concomitant up regulation of IFN-gamma-
inducible genes (Duque et al., 2009) and activation of the kynurenine
pathway (Vidal et al., 2015) while impairing angiogenic activity (Hoch
et al., 2012). Our studies advance these ﬁndings in a meaningful way
by providing a direct mechanistic link between these processes.
Our ﬁndings also have important implications with respect to the
clinical application of MSCs. For example, Fgf2 supplementation is fre-
quently used to drive MSC expansion to enhance cell yields for clinical
therapies but our data indicate this enriches for populations with a
pro-angiogenic phenotype. This result predicts such cells are ill suited
for treating conditions wherein angiogenesis is detrimental, such as
joint repair, or acute and chronic inﬂammatory conditions as demon-
strated herein for bleomycin-induced lung injury. In the latter case,
our data suggest that naïve or Fgf2-pretreated MSCs are not “pro-in-
ﬂammatory” since they do not secrete detectable levels of IL-1α, IL-1βand Tnf. Moreover, we are unaware of any studies that suggest admin-
istration of these cells in vivo induces an acute inﬂammatory response.
Alternatively, our data suggest these cells are less potently anti-
inﬂammatory due to elevated expression levels of the angiogenins IL-
6, IL-8, and Ccl2, which also exhibit potent chemotactic activity for leu-
kocytes and neutrophils, and lower expression of anti-inﬂammatory
mediators, such as Il1rn. Owing to the fact that Hif-1-alpha is a potent
inducer of Twist1 (Yang et al., 2008) our data also provide mechanistic
insight into howhypoxic preconditioningpotentiates the angiogenic ac-
tivity of MSCs.
Similarly, our data also provides mechanistic insight into how IFN-
gamma licenses the anti-inﬂammatory and immuno-modulatory activ-
ities of MSCs by identifying Twist1 as a target of IFN-gamma action and
linking Twist1 down regulation with elevated expression of Ido1, Il1rn,
andHMOX1, increased secretion of Pge2, and reduced IL-6 secretion. Im-
portantly, IFN-gamma-mediated Twist1 down regulation also impedes
MSC growth and CFU-F activity and enhances cellular senescence and
apoptosis. This is consistent with the fact that interferons are known
to exhibit growth repressive effects by inhibiting expression of Rpl23a
(Jiang et al., 1997), which is also a Twist1 target in MSCs. Indeed, recent
studies indicate that IFN-gamma potentiates inﬂammatory activation of
macrophages by translational suppression of repressors of inﬂamma-
tion such asHes1, a basic helix–loop–helix protein, and down regulation
of mTorc1 via Ido1-mediated tryptophan depletion (Su et al., 2015).
Similarly, our studies indicate that IFN-gamma-mediated induction of
Ido1 in MSCs, which confer immuno-suppressive properties onto cells,
occurs via inhibition of Twist1. Whether the latter results from speciﬁc
translational suppression of this protein or post-translational modiﬁca-
tions that affect its stability and/or function are unknown. Nevertheless,
careful consideration should be given to how culture supplements and/
or pre-conditioning regimens alter the cellular composition ofMSC pop-
ulations and their therapeutic efﬁcacy via effects on Twist1 expression.
To facilitate this process, we have developed a CLinical Indications Pre-
diction (CLIP) scale (Fig. 7),which can be used to inform clinical trials by
determining the suitability of a givenMSCdonor population for a specif-
ic disease indication and/or to develop improvedmanufacturing strate-
gies to develop disease-speciﬁc cell therapy products.
In summary, our data suggest that intrinsic differences in TWIST1
levels induce cell fate changes that simultaneously alter the progenitor
and effector properties of MSCs in a predictable manner. Therefore, an
important area of future study will be to determine the extent by
which stochastic and deterministic processes regulate TWIST1
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based studies conducted in Drosophila have determined that Twist
modulates transcriptional regulatory networks with complex logical
outputs by binding to over 2000 cis-regulatory elements (Sandmann
et al., 2007; Ozdemir et al., 2011). Twist1 targets identiﬁed in MSCs
also map to critical nodes within multiple gene regulatory networks,
which explains in part how changes in its expression reliably predicts
donor-to-donor differences in the biological properties of MSC popula-
tions. However, the ﬁner points of Twist1 action in MSCs, such as how
it represses Ido1 and stimulates Ccl2 transcription by direct promoter
binding, remain a fertile area of study. Further scrutiny of Twist1
regulated pathways, protein binding partners, and targets of direct tran-
scriptional regulation will provide additional insight into the mecha-
nisms that drive population heterogeneity, which directly impact
therapeutic efﬁcacy, and also reveal other Twist1 surrogates, such as
Fgfr2IIIc, that can be used to screen populations pre- and post-
manufacturing to determine their suitability for treating a speciﬁc dis-
ease indication in human patients.
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